EPCAM and breast carcinoma: In 2004, the U.S. Food and Drug Administration (FDA) approved an epithelial cell adhesion molecule (EpCAM)-dependent technique for use as a prognostic biomarker in breast cancer [4], which was then expanded for use in prostate and colorectal cancer patients [5].